Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine
prnewswire.com
news
2022-10-17 00:00:00

ROCKVILLE, Md. and SUZHOU, China, Oct. 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced that results of higher-dose cohorts in a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese participants with overweight or obesity have been published online in eClinicalMedicine (https://www.
